Is CytomX Therapeutics, Inc. (CTMX) a Buy, Sell, or Hold?
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$3.68 USD
$0.02 (0.55%)
- Volume
- 5.14M
- Average Volume
- 4.22M
- Market Capitalization
- $591.83M
- P/E Ratio
- -10.19
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $8.21
- Year Low
- $1.72
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.38
NUMBER OF INSIDERS BUYING (LAST 12 MONTHS)
20
NUMBER OF INSIDERS SELLING (LAST 12 MONTHS)
6
AMOUNT OF INSIDER SELLING (LAST 12 MONTHS)
$ 294.48K
CTMX Estimated and Actual Revenue by Quarter
Get MSFT Insider Trade Alerts
CTMX Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Su Zhen | director | 2026-06-17 | A-Award | 2.96 | 2026-06-22 |
| Young Matthew P. | director | 2026-06-17 | A-Award | 2.96 | 2026-06-22 |
| Mohindru Mani | director | 2026-06-17 | A-Award | 2.96 | 2026-06-22 |
| Meyers James R | director | 2026-06-17 | A-Award | 2.96 | 2026-06-22 |
| Gilbert Halley E | director | 2026-06-17 | A-Award | 2.96 | 2026-06-22 |
| Ashworth Alan | director | 2026-06-17 | A-Award | 2.96 | 2026-06-22 |
| Jones Elaine V | director | 2026-06-17 | A-Award | 2.96 | 2026-06-22 |
| Ogden Christopher | officer: Chief Financial Officer | 2026-06-15 | S-Sale | 3.05 | 2026-06-17 |
| Chu Yu-Waye | officer: Chief Medical Officer | 2026-03-17 | S-Sale | 6.423 | 2026-03-19 |
| McCarthy Sean A. | director, officer: CEO | 2026-03-17 | S-Sale | 6.423 | 2026-03-19 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2026-03-17 | S-Sale | 6.423 | 2026-03-19 |
| Ogden Christopher | officer: Chief Financial Officer | 2026-03-17 | S-Sale | 6.423 | 2026-03-19 |
| Lester Rachael | officer: Chief Business Officer | 2026-02-02 | A-Award | 6.09 | 2026-02-04 |
| Lester Rachael | officer: Chief Business Officer | 2026-02-02 | A-Award | 0 | 2026-02-04 |
| Lester Rachael | officer: Chief Business Officer | 2026-02-02 | A-Award | 0 | 2026-02-04 |
| Chu Yu-Waye | officer: Chief Medical Officer | 2026-02-02 | A-Award | 6.09 | 2026-02-04 |
| Chu Yu-Waye | officer: Chief Medical Officer | 2026-02-02 | A-Award | 0 | 2026-02-04 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2026-02-02 | A-Award | 0 | 2026-02-04 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2026-02-02 | A-Award | 6.09 | 2026-02-04 |
| Ogden Christopher | officer: Chief Financial Officer | 2026-02-02 | A-Award | 6.09 | 2026-02-04 |
| Ogden Christopher | officer: Chief Financial Officer | 2026-02-02 | A-Award | 0 | 2026-02-04 |
| McCarthy Sean A. | director, officer: CEO | 2026-02-02 | A-Award | 0 | 2026-02-04 |
| McCarthy Sean A. | director, officer: CEO | 2026-02-02 | A-Award | 6.09 | 2026-02-04 |
| McCarthy Sean A. | director, officer: CEO | 2025-11-06 | S-Sale | 4.5377 | 2025-11-10 |
| Lester Rachael | officer: Chief Business Officer | 2025-10-20 | A-Award | 3.74 | 2025-10-29 |
| Lester Rachael | 2025-10-20 | 0 | 2025-10-29 | ||
| McCarthy Sean A. | director, officer: CEO | 2025-09-26 | A-Award | 2.9 | 2025-09-30 |
| McCarthy Sean A. | director, officer: CEO | 2025-09-26 | A-Award | 0 | 2025-09-30 |
| Chu Yu-Waye | officer: Chief Medical Officer | 2025-09-26 | A-Award | 2.9 | 2025-09-30 |
| Chu Yu-Waye | officer: Chief Medical Officer | 2025-09-26 | A-Award | 0 | 2025-09-30 |
| Ogden Christopher | officer: Chief Financial Officer | 2025-09-26 | A-Award | 2.9 | 2025-09-30 |
| Ogden Christopher | officer: Chief Financial Officer | 2025-09-26 | A-Award | 0 | 2025-09-30 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2025-09-26 | A-Award | 2.9 | 2025-09-30 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2025-09-26 | A-Award | 0 | 2025-09-30 |
| Ogden Christopher | officer: Chief Financial Officer | 2025-06-13 | M-Exempt | 0 | 2025-06-17 |
| Ogden Christopher | officer: Chief Financial Officer | 2025-06-16 | S-Sale | 2.6889 | 2025-06-17 |
| Ogden Christopher | officer: Chief Financial Officer | 2025-06-13 | S-Sale | 2.9503 | 2025-06-17 |
| Ogden Christopher | officer: Chief Financial Officer | 2025-06-13 | M-Exempt | 0 | 2025-06-17 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2025-06-13 | M-Exempt | 0 | 2025-06-17 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2025-06-16 | S-Sale | 2.689 | 2025-06-17 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2025-06-13 | M-Exempt | 0 | 2025-06-17 |
| McCarthy Sean A. | director, officer: CEO | 2025-06-13 | M-Exempt | 0 | 2025-06-17 |
| McCarthy Sean A. | director, officer: CEO | 2025-06-16 | S-Sale | 2.6889 | 2025-06-17 |
| McCarthy Sean A. | director, officer: CEO | 2025-06-13 | M-Exempt | 0 | 2025-06-17 |
| Su Zhen | director | 2025-06-11 | A-Award | 2.82 | 2025-06-13 |
| Young Matthew P. | director | 2025-06-11 | A-Award | 2.82 | 2025-06-13 |
| Mohindru Mani | director | 2025-06-11 | A-Award | 2.82 | 2025-06-13 |
| Meyers James R | director | 2025-06-11 | A-Award | 2.82 | 2025-06-13 |
| Jones Elaine V | director | 2025-06-11 | A-Award | 2.82 | 2025-06-13 |
| Gilbert Halley E | director | 2025-06-11 | A-Award | 2.82 | 2025-06-13 |
| Ashworth Alan | director | 2025-06-11 | A-Award | 2.82 | 2025-06-13 |
| McCarthy Sean A. | director, officer: CEO | 2025-03-18 | S-Sale | 0.599 | 2025-03-20 |
| Ogden Christopher | officer: Chief Financial Officer | 2025-03-18 | S-Sale | 0.599 | 2025-03-20 |
| Chu Yu-Waye | officer: Chief Medical Officer | 2025-03-18 | S-Sale | 0.599 | 2025-03-20 |
| ROWLAND LLOYD A | officer: General Counsel | 2025-03-18 | S-Sale | 0.599 | 2025-03-20 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2025-03-18 | S-Sale | 0.599 | 2025-03-20 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2025-02-04 | A-Award | 0 | 2025-02-10 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2025-02-04 | A-Award | 0 | 2025-02-10 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2025-02-04 | A-Award | 0.864 | 2025-02-10 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2025-02-04 | A-Award | 0 | 2025-02-06 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2025-02-04 | A-Award | 0 | 2025-02-06 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2025-02-04 | A-Award | 0.864 | 2025-02-06 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2025-02-04 | A-Award | 0.864 | 2025-02-06 |
| Chu Yu-Waye | officer: Chief Medical Officer | 2025-02-04 | A-Award | 0.864 | 2025-02-06 |
| Chu Yu-Waye | officer: Chief Medical Officer | 2025-02-04 | A-Award | 0 | 2025-02-06 |
| Chu Yu-Waye | officer: Chief Medical Officer | 2025-02-04 | A-Award | 0.864 | 2025-02-06 |
| Chu Yu-Waye | officer: Chief Medical Officer | 2025-02-04 | A-Award | 0 | 2025-02-06 |
| Ogden Christopher | officer: Chief Financial Officer | 2025-02-04 | A-Award | 0.864 | 2025-02-06 |
| Ogden Christopher | officer: Chief Financial Officer | 2025-02-04 | A-Award | 0 | 2025-02-06 |
| Ogden Christopher | officer: Chief Financial Officer | 2025-02-04 | A-Award | 0 | 2025-02-06 |
| Ogden Christopher | officer: Chief Financial Officer | 2025-02-04 | A-Award | 0.864 | 2025-02-06 |
| McCarthy Sean A. | director, officer: CEO | 2025-02-04 | A-Award | 0 | 2025-02-06 |
| McCarthy Sean A. | director, officer: CEO | 2025-02-04 | A-Award | 0 | 2025-02-06 |
| McCarthy Sean A. | director, officer: CEO | 2025-02-04 | A-Award | 0.864 | 2025-02-06 |
| McCarthy Sean A. | director, officer: CEO | 2025-02-04 | A-Award | 0.864 | 2025-02-06 |
| Landau Jeffrey B | officer: Chief Business Officer | 2024-08-20 | M-Exempt | 0 | 2024-08-22 |
| Landau Jeffrey B | officer: Chief Business Officer | 2024-08-20 | S-Sale | 1.2291 | 2024-08-22 |
| Landau Jeffrey B | officer: Chief Business Officer | 2024-08-20 | M-Exempt | 0 | 2024-08-22 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2024-08-20 | M-Exempt | 0 | 2024-08-22 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2024-08-20 | S-Sale | 1.2291 | 2024-08-22 |
| BELVIN MARCIA | officer: SVP, Chief Scientific Officer | 2024-08-20 | M-Exempt | 0 | 2024-08-22 |
| ROWLAND LLOYD A | officer: General Counsel | 2024-08-20 | M-Exempt | 0 | 2024-08-22 |
| ROWLAND LLOYD A | officer: General Counsel | 2024-08-20 | S-Sale | 1.2291 | 2024-08-22 |
| ROWLAND LLOYD A | officer: General Counsel | 2024-08-20 | M-Exempt | 0 | 2024-08-22 |
| Ogden Christopher | officer: Chief Financial Officer | 2024-08-20 | M-Exempt | 0 | 2024-08-22 |
| Ogden Christopher | officer: Chief Financial Officer | 2024-08-20 | S-Sale | 1.2291 | 2024-08-22 |
| Ogden Christopher | officer: Chief Financial Officer | 2024-08-20 | M-Exempt | 0 | 2024-08-22 |
| McCarthy Sean A. | director, officer: CEO | 2024-08-20 | M-Exempt | 0 | 2024-08-22 |
| McCarthy Sean A. | director, officer: CEO | 2024-08-20 | S-Sale | 1.2291 | 2024-08-22 |
| McCarthy Sean A. | director, officer: CEO | 2024-08-20 | M-Exempt | 0 | 2024-08-22 |
| Ogden Christopher | officer: Chief Financial Officer | 2024-06-12 | A-Award | 0 | 2024-06-14 |
| Ogden Christopher | officer: Chief Financial Officer | 2024-06-12 | A-Award | 1.49 | 2024-06-14 |
| Young Matthew P. | director | 2024-05-15 | A-Award | 1.96 | 2024-05-17 |
| Su Zhen | director | 2024-05-15 | A-Award | 1.96 | 2024-05-17 |
| Mohindru Mani | director | 2024-05-15 | A-Award | 1.98 | 2024-05-17 |
| Meyers James R | director | 2024-05-15 | A-Award | 1.96 | 2024-05-17 |
| Jones Elaine V | director | 2024-05-15 | A-Award | 1.96 | 2024-05-17 |
| Gilbert Halley E | director | 2024-05-15 | A-Award | 1.96 | 2024-05-17 |
| Ashworth Alan | director | 2024-05-15 | A-Award | 1.96 | 2024-05-17 |
| McCarthy Sean A. | director, officer: CEO | 2024-03-26 | M-Exempt | 1.5749 | 2024-03-28 |